carvedilol has been researched along with Right Ventricular Dysfunction in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis." | 7.81 | Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. ( Breitling, S; Friedberg, MK; Honjo, O; Kato, H; Kuebler, WM; Okumura, K; Sun, M, 2015) |
| "Genes encoding proteins in the cardiac hypertrophy and protein ubiquitination pathways were downregulated in the RV by carvedilol, while genes encoding proteins in the mitochondrial dysfunction pathway were upregulated by carvedilol." | 5.39 | Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. ( Bogaard, HJ; Drake, JI; Dumur, CI; Fawcett, P; Gomez-Arroyo, J; Kraskauskas, D; Natarajan, R; Voelkel, NF, 2013) |
| " • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis." | 3.81 | Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. ( Breitling, S; Friedberg, MK; Honjo, O; Kato, H; Kuebler, WM; Okumura, K; Sun, M, 2015) |
| "To assess the effect of the adrenergic receptor blocker carvedilol on the pulmonary circulation and right heart in experimental pulmonary hypertension in rats." | 3.76 | Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. ( Abbate, A; Bogaard, HJ; Chang, PJ; Chau, VQ; Hoke, NN; Kasper, M; Kraskauskas, D; Mizuno, S; Natarajan, R; Salloum, FN; Voelkel, NF, 2010) |
| "After appropriate pharmacologic treatment of her hyperthyroidism, she had complete resolution of her cardiomyopathy." | 1.40 | Biventricular Takotsubo cardiomyopathy in Graves hyperthyroidism. ( Perkins, MJ; Schachter, DT, 2014) |
| "Genes encoding proteins in the cardiac hypertrophy and protein ubiquitination pathways were downregulated in the RV by carvedilol, while genes encoding proteins in the mitochondrial dysfunction pathway were upregulated by carvedilol." | 1.39 | Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. ( Bogaard, HJ; Drake, JI; Dumur, CI; Fawcett, P; Gomez-Arroyo, J; Kraskauskas, D; Natarajan, R; Voelkel, NF, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thenappan, T | 1 |
| Weir, EK | 1 |
| Prins, KW | 1 |
| Pritzker, MR | 1 |
| Archer, SL | 1 |
| Liu, E | 1 |
| Guha, A | 1 |
| Jia, K | 1 |
| Ayers, AM | 1 |
| Boudoulas, KD | 1 |
| Bertino, E | 1 |
| Franco, V | 1 |
| Drake, JI | 1 |
| Gomez-Arroyo, J | 1 |
| Dumur, CI | 1 |
| Kraskauskas, D | 2 |
| Natarajan, R | 2 |
| Bogaard, HJ | 3 |
| Fawcett, P | 1 |
| Voelkel, NF | 3 |
| Perkins, MJ | 1 |
| Schachter, DT | 1 |
| Grinnan, D | 1 |
| Grizzard, J | 1 |
| Van Tassell, B | 1 |
| Abbate, A | 2 |
| DeWilde, C | 1 |
| Priday, A | 1 |
| Rea, G | 1 |
| Valente, T | 1 |
| de Rosa, N | 1 |
| Muto, M | 1 |
| Berritto, D | 1 |
| Bocchino, M | 1 |
| Okumura, K | 1 |
| Kato, H | 1 |
| Honjo, O | 1 |
| Breitling, S | 1 |
| Kuebler, WM | 1 |
| Sun, M | 1 |
| Friedberg, MK | 1 |
| Mizuno, S | 1 |
| Chang, PJ | 1 |
| Chau, VQ | 1 |
| Hoke, NN | 1 |
| Kasper, M | 1 |
| Salloum, FN | 1 |
| Giardini, A | 1 |
| Lovato, L | 1 |
| Donti, A | 1 |
| Formigari, R | 1 |
| Gargiulo, G | 1 |
| Picchio, FM | 1 |
| Fattori, R | 1 |
| Doughan, AR | 1 |
| McConnell, ME | 1 |
| Book, WM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Beta Blockers in Pulmonary Arterial Hypertension (PAH) A Pilot Study of Efficacy and Safety[NCT02120339] | Phase 1 | 5 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Low enrollment) | ||
| Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension[NCT00964678] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in right ventricular ejection fraction is measured by cardiac magnetic resonance imaging, using the method of disks with the reading radiologist being blinded to before and after images. Cardiac magnetic resonance imaging was done at baseline and 6 months only (NCT00964678)
Timeframe: baseline, 6 months
| Intervention | % RVEF (Mean) |
|---|---|
| Carvedilol | 10.4 |
(NCT00964678)
Timeframe: baseline and 6 months
| Intervention | feet (Number) | ||||
|---|---|---|---|---|---|
| Participant 1 | Participant 2 | Participant 3 | Participant 5 | Participant 6 | |
| Carvedilol | 45 | 160 | 35 | 5 | 96 |
right ventricular end systolic volume determined by MRI (NCT00964678)
Timeframe: baseline and 6 months
| Intervention | mL (Number) | |||||
|---|---|---|---|---|---|---|
| Participant 1 | Participant 2 | Participant 3 | Participant 4 | Participant 5 | Participant 6 | |
| Carvedilol | 3 | 14 | 56 | 11 | 27 | 25 |
Higher values indicate a better outcome. (NCT00964678)
Timeframe: baseline and 6 months
| Intervention | centimeters (Number) | ||||
|---|---|---|---|---|---|
| Participant 1 | Participant 2 | Participant 4 | Participant 5 | Participant 6 | |
| Carvedilol | 0.4 | -0.08 | -0.12 | 0.45 | 0.08 |
1 trial available for carvedilol and Right Ventricular Dysfunction
| Article | Year |
|---|---|
Treatment of group I pulmonary arterial hypertension with carvedilol is safe.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Drug Administration Schedule; Familial Pr | 2014 |
9 other studies available for carvedilol and Right Ventricular Dysfunction
| Article | Year |
|---|---|
Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.
Topics: Antihypertensive Agents; Carvedilol; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; M | 2021 |
Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carbazoles; Carcin | 2017 |
Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.
Topics: Animals; Carbazoles; Cardiomegaly; Carvedilol; Cluster Analysis; Gene Expression Profiling; Gene Exp | 2013 |
Biventricular Takotsubo cardiomyopathy in Graves hyperthyroidism.
Topics: Adult; Carbazoles; Carvedilol; Drug Therapy, Combination; Electrocardiography; Female; Graves Diseas | 2014 |
Pulmonary capillary hemangiomatosis: a diagnostic challenge.
Topics: Carbazoles; Carvedilol; Delayed Diagnosis; Disease Progression; Furosemide; Granuloma, Pyogenic; Hum | 2015 |
Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Connective Tissue Growth Factor; Fibrosis; | 2015 |
Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
Topics: Adrenergic Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Hypertension, Pulmo | 2010 |
A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Electrocardiography; Exercis | 2007 |
Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Female; Follow-Up Studies; Humans; Male; | 2007 |